You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Factor V Leiden mutation and PAI-1 gene 4G/5G genotype in thrombotic patients with Behcet's disease

Gurgey, Aytemiza; Balta, Gunayb; Boyvat, Ayseb

Blood Coagulation & Fibrinolysis:
Original Articles
Abstract

Behcet's disease is a chronic systemic vasculitis with particular systemic features including thrombotic events. The present study was designed to analyse the role of the factor V Leiden and the prothrombin G20210A mutations and plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk of patients with Behcet's disease. A total of 50 unrelated patients with Behcet's disease (34 male, 16 female) were the subjects of the study. Twenty-seven of 50 patients with a history of thrombosis comprised group 1, and 23 patients with no thrombosis comprised group 2. In group 1, nine of the 27 patients (33%) were found to have the factor V Leiden mutation (7.1% in healthy population), and the 4G/4G genotype was found in 23% of the patients (26% in control). No patient had the prothrombin G20210A mutation (2.2% in healthy control). In group 2, two patients (9%) had the factor V Leiden and one patient (4%) had the prothrombin G20210A mutations. The 4G/4G polymorphism was found in 30.5% of the patients. The differences in the frequencies of factor V Leiden mutation between group 1 and group 2 (odds ratio, 5.3; 95% confidence interval, 1.0–27.5) and between group 1 and the healthy population were statistically significant (P < 0.05). No statistically significant association was found for the prothrombin G20210A mutation and the 4G/5G genotype between the two groups or between each group and the healthy population, indicating that the prothrombin G20210A mutation and the 4G/4G polymorphism do not play a role in the development of thrombosis in Behcet's disease. These data suggested that the factor V Leiden mutation might be a risk factor for the development of thrombosis in Behcet's disease patients.

Author Information

aDepartment of Pediatric Hematology, Hacettepe University Medical School, Ankara, Turkey and bDepartment of Dermatology, Ankara University, Ibni Sina Hospital, Ankara, Turkey.

Correspondence and requests for reprints to Aytemiz Gurgey, M.D., Department of Pediatric Hematology, Hacettepe University Medical School, 06100 Sihhiye, Ankara, Turkey. Tel/fax: (+90) 312 324 16 81; e-mail: agurgey@hacettepe.edu.tr

Received 28 February 2002 Revised 11 June 2002 Accepted 18 June 2002

© 2003 Lippincott Williams & Wilkins, Inc.